Bacterial resistance due to indiscriminate use of the carbapenems meropenem and imipenem: an integrative review
DOI:
https://doi.org/10.33448/rsd-v11i7.30195Keywords:
Health teaching; Bacterial resistance; Carbapenems; Meropenem; Imipenem; Resistance mechanisms.Abstract
Antimicrobials are substances that kill or inhibit the growth of microorganisms and their prescription in hospitals is mainly based on the effectiveness of the drug. Carbapenems are antimicrobials resistant to the action of β-lactamases and AmpC. Meropenem and imipenem are antibiotics that belong to this class and represent the ß-lactams with the highest antimicrobial potency, meropenem has a superior in vitro activity against gram-negatives, but imipenem is slightly more active against gram-positives. Objective: For him, the objective was to describe the occurrence of bacterial resistance due to the discriminated use of the carbapenems mer openem and imipenem, causing bacterial multi-resistance. Method: integrative study of Bibliography review in LILACS, PUBMED/MEDELINE and SCIELO databases, between 2012 and 2022. Select 75 articles, from the 10 codes used in the elaboration of the work. The results that bacterial multidrug resistance have created in recent years of infection by infection by multidrug resistant bacteria and by multidrug resistant bacteria, due to the unnecessary use of antibiotics and the indiscriminate challenge to select microorganisms, to which the influence of others of resistance leads, putting at risk human health, which leads to an extension of hospitalization days, increased costs and higher mortality, you escape new therapeutic options for the treatment of infections with multidrug-resistant bacteria. Concluding that prescriptions play an important role in promoting the rational use of antimicrobials, it is not enough to have an accurate diagnosis and an adequate selection of the antimicrobial if the prescription is not rigorously elaborated and complete in all its aspects. It is necessary that the use of antibiotics is indicated, as much for the health as for the bacterial population, as the indication that it is effective against antibiotics against infectious diseases.
References
Anvisa. (2013ª). Nota Técnica Nº 01/2013 - Medidas de prevenção e controle de infecções por enterobactérias multiresistentes. Agência Nacional de Vigilância Sanitária.
Baptista, M. G. F. M. (2013). Mecanismos de Resistência aos Antibióticos,monografia (Dissertação de Mestrado) Curso de Mestrado Integrado em Ciências Farmacêuticas, Universidade Lusófona de Humanidades e Tecnologia, Lisboa. 42.
Blair, J. M. et al. (2017). Molecular Mechanisms of Antibiotic Resistance. Nature. 13(2), 42- 51.
doi: 10.18468/estcien. 2017v7n2.p45-57.
Costa., Anderson-Luiz., Silva-Junior., Antonio-Carlos-Souza. (2016) Resistência bacteriana aos antibióticos e Saúde Pública: uma breve revisão de literatura. Estação Científica (Unifap), Macapá. 7(2),45-57.
Cotrim, E. R.; Rocha, R. D. R.; Ferreira, M. F. R. (2012). Klebsiella pneumoniae Carbapenemase–KPC em Enterobacteriaceae: o desafio das bactérias multirresistentes. Revista do Centro Universitário Newton Paiva. 5(1).
Centers for Disease Control and Prevention -CDC. (2013). Antibiotic Resistance Threats in the United States. http://www.cdc.gov/drugresistance/threat-report-2013/index.html.
Clinical and laboratory standards institute. (2010). Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement. CLSI document M100-S20. Waine, PA, USA.
Dhillon, S. (2018). Meropenem/VaborbactamA Review in Complicated Urinary Tract Infections. Drugs. 78(12),1259–70
Durand, A. G., et al. (2019). Antibiotic discovery: history, methods and perspectives. International Journal of Antimicrobial Agents, 53(4),371–382.doi: 10.1016/j.ijantimicag.2018.11.010.
Dhillon,S. (2018). Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections. Drugs. 78(12),1259–70.
Elshamy, A.A.& Aboshanab, K.M. (2020). A review on bacterial resistance to carbapenems: Epidemiology, detection and treatment options. Futur Scioa.6(3).
González-Mendoza,J.,Maguiña-Vargas.C.,González-Ponce.F.M.(2019). Resistência aos antibióticos: um problema muito sério. certificado médico Peru.36(2),145-51.
Laboratoires Merck Sharp., & Dohme .(2018) – Chibret. Recarbrio. França.
Nordmann, P. et al. (2014). Carbapenemase-producing Enterobactericeae: overview of a major public health challenge. Med Mal Infect, (44), 51-56.
Nikaido, H., Pagès, J. M. (2012). Broadspecificity efflux pumps and their role in multidrug resistance of Gram-negative bacteria. Fems Microbiology Reviews. 36(2),340-63.
Nogueira, H. S. et al. (2016). Antibacterianos: principais classes, mecanismos de ação e resistência. Unimontes Científica, Montes Claros, 18(2).
Organização Mundial da Saúde. (2020). Resistência antimicrobiana. nota descritiva. Genebra: OMS.
Opas. (2017). VII Workshop Nacional do Codex Alimentarius. Para ação integrada contra a resistência antimicrobiana, 25 (6).
Oliveira, S. C. R., Mata, L. C. C.(2017). Uso de Carbapenêmicos em uma unidade de terapia intensiva adulto em um hospital de Curvelo Minas Gerais. 2017 Acesso em 12 fev. 2019.
Pereira, P.S., Borghi, M., Araújo, C.F. et al. (2015). Clonal dissemination of oxa-370- producing Klebsiella pneumoniae in Rio de Janeiro, Brazil. Antimicrobial Agents Chemother. (59),4453-4456.
Penido, C. (2019). Carbapenêmicos (beta-lactâmicos). < https://edisciplinas. usp.br/ pluginfile.php/3480829/.../Carbapenêmicos%20v1.pdf?> Acesso em 15 de mar. de 2019.
Queiroz, G. M. et.al. (2012). Multirresistência microbiana e opções terapêuticas disponíveis. Rev. Bras. Clin. Med., São Paulo. 10(2), 132-138.
Qib, A. I. et al. (2020). Antibiotic susceptibilities and prevalence of Methicillin resistant Staphylococcus aureus (Mrsa) isolated from bovine milk in Pakistan. Acta tropica, (176),168–172, doi: 10.1016/j.actatropica.
Ribeiro, J. L., Comarella, L. (2015). Bactérias Multirresistentes e Emergência da Resistência tipo New Delhi Methalo-β-Lactamase – 1 (NDM – 1). Revista Uniandrade, 16(2), 109-118.
Sandi, N. et al. (2015). Staphylococcus aureus Vaccine Candidate from Mrsa Isolates: The Prospect of a Multivalent Vaccine. American Journal of Infectious Diseases, 11(3),54-62. doi: 10.3844/ajidsp.
Tortora, G. J., Funke, B. R., & Case, C. L. (2012) Microbiologia. Porto Alegre: Artmed 10ª Ed,P53.
Tormin, S. C. et al. (2016). Análise do efeito bactericida do ozônio sobre bactérias multirresistentes. Arq Med Hosp Fac Cienc Med Santa Casa, São Paulo, (61), 138-141.
Uddin, M. J., Ahn, J. (2017). Associations between resistance phenotype and gene expression in response to serial exposure to oxacillin and ciprofloxacin in Staphylococcus aureus. Letters in Applied Microbiology, 65(6), 462-468. doi: 10.1111/lam.12808
Velkov, T. R.K. et. al. (2013). Pharmacology of polymyxins: new insights into an ‘old’ class of antibiotics. Futur Microbiol. 8(6),711–24.
Vanegas-Múnera, J.M., Jiménez-Quiceno, J.N. (2020). Resistência antimicrobiana no século XXI: rumo a uma era pós-antibiótica? Rev. Fac. Nac. Saúde Pública 38(1): e337759-e65.
World health organization- who. (2017). Model list of essential medicines. 20th list. Geneva: World Health Organisation.
(12),98067-98081.
Young, K., Painter,R.E., Raghoobar,S.L., Hairston, N.N., Racine,F., Wisniewski,D., Balibar,C.J., Villafania, A., Zhang, R., Sahm, D.F., Blizzard,T., Murgolo, N., Hammond, M.L., Motyl,M.R. (2019). In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa. BMC Microbiol 19:150. 10.1186/s12866-019-1522-7. Crossref. PubMed.
World Healt Organization. (2017). WHO publishes list of bacteria for which new antibiotics are urgently needed [Internet]. Geneva. . https://www.who.int/
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Aridson Erick Ferreira da Silva; Omero Martins Rodrigues Junior
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish with this journal agree to the following terms:
1) Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
2) Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
3) Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
